Page last updated: 2024-08-25

almagate and Angiogenesis, Pathologic

almagate has been researched along with Angiogenesis, Pathologic in 18 studies

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's13 (72.22)29.6817
2010's3 (16.67)24.3611
2020's2 (11.11)2.80

Authors

AuthorsStudies
Hara, H; Nakamura, S1
Andrade, N; Araújo E Silva, PM; Crispim Ribeiro, J; de Moraes, MO; Fechine, FV; Savio, D1
Raczyńska, D; Raczyńska, K; Zorena, K1
Hong, J; Li, Y; Xu, J1
Avitabile, T; Bonfiglio, V; Casuccio, A; Cennamo, G; Cillino, S; Furino, C; Longo, A; Pani, L; Parisi, G; Parravano, M; Reibaldi, M; Russo, A; Uva, MG; Xoxi, E1
Donati, G; Mendrinos, E; Pournaras, CJ1
Barakat, MR; Kaiser, PK1
Funatsu, H1
Claes, A; Hovinga, KE; Leenders, WP; Musters, GD; Peter Vandertop, W; Richel, DJ; Stalpers, LJ; van Furth, WR; Verhoeff, JJ1
Adamis, AP; Ng, EW1
Doggrell, SA1
Canny, MD; De Erkenez, A; Jucker, F; Krilleke, D; Lee, JH; Ng, YS; Pardi, A; Shima, DT1
Adamis, AP; Calias, P; Cunningham, ET; Guyer, DR; Ng, EW; Shima, DT1
Ducharme, JF; Filippopoulos, T; Krzystolik, MG; Loewenstein, JI1
Michels, S; Rosenfeld, PJ; Schmidt-Erfurth, U1
Cavalli, M; Gatto, B1
Bienias, W; Nowak, JZ1
Joussen, AM1

Reviews

11 review(s) available for almagate and Angiogenesis, Pathologic

ArticleYear
[Prospects and Challenges of Anti-VEGF Drug Treatment for Pathological Angiogenesis of the Retina].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2021, Volume: 141, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Diabetic Retinopathy; Drug Development; Humans; Macular Degeneration; Mice; Molecular Targeted Therapy; Neovascularization, Pathologic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retina; Retinal Vein Occlusion; Vascular Endothelial Growth Factor A

2021
Biomarkers in diabetic retinopathy and the therapeutic implications.
    Mediators of inflammation, 2013, Volume: 2013

    Topics: Adalimumab; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Aptamers, Nucleotide; Bevacizumab; Biomarkers; Diabetic Retinopathy; Etanercept; Eye Proteins; Humans; Immunoglobulin G; Infliximab; Interleukin-12; Mice; Neovascularization, Pathologic; Nerve Growth Factors; Quality of Life; Ranibizumab; Receptors, Tumor Necrosis Factor; Rituximab; Serpins; Somatomedins; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A

2013
Progress of anti-vascular endothelial growth factor therapy for ocular neovascular disease: benefits and challenges.
    Chinese medical journal, 2014, Volume: 127, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Eye; Humans; Neovascularization, Pathologic; Ranibizumab; Vascular Endothelial Growth Factor A

2014
VEGF inhibitors for the treatment of neovascular age-related macular degeneration.
    Expert opinion on investigational drugs, 2009, Volume: 18, Issue:5

    Topics: Animals; Aptamers, Nucleotide; Humans; Macular Degeneration; Neovascularization, Pathologic; Treatment Outcome; Vascular Endothelial Growth Factor A

2009
[Progress in therapy for and diagnosis of diabetic complications--diabetic retinopathies].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2009, Apr-10, Volume: 98, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Drug Design; Humans; Neovascularization, Pathologic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A

2009
Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.
    Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2005, Volume: 40, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Macular Degeneration; Neovascularization, Pathologic; Treatment Outcome; Vascular Endothelial Growth Factor A

2005
Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:8

    Topics: Angiogenesis Inhibitors; Animals; Aptamers, Nucleotide; Humans; Macular Degeneration; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A

2005
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
    Nature reviews. Drug discovery, 2006, Volume: 5, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Aptamers, Nucleotide; Clinical Trials as Topic; Diabetic Retinopathy; Drug Delivery Systems; Eye; Eye Diseases; Humans; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A

2006
Promising new treatments for neovascular age-related macular degeneration.
    Expert opinion on investigational drugs, 2006, Volume: 15, Issue:7

    Topics: Aging; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Capillary Permeability; Cholestanols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Double-Blind Method; Drug Design; Drugs, Investigational; Eye Proteins; Humans; Injections; Lactates; Macular Degeneration; Models, Animal; Multicenter Studies as Topic; Neovascularization, Pathologic; Nerve Growth Factors; Pigment Epithelium of Eye; Protein Isoforms; Randomized Controlled Trials as Topic; RNA Interference; RNA, Small Interfering; Serpins; Stilbenes; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vitreous Body

2006
[Age-related macular degeneration (AMD): etiopathogenesis and therapeutic strategies].
    Postepy higieny i medycyny doswiadczalnej (Online), 2007, Volume: 61

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antioxidants; Aptamers, Nucleotide; Bevacizumab; Humans; Lipofuscin; Macular Degeneration; Neovascularization, Pathologic; Photochemotherapy; Pregnadienediols; Ranibizumab; Retinal Drusen; Triamcinolone Acetonide

2007
[Molecular pathogenesis of ocular vascular disease--anti-angiogenesis as a therapeutic concept].
    Deutsche medizinische Wochenschrift (1946), 2007, Jun-08, Volume: 132, Issue:23

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Angiopathies; Diabetic Retinopathy; Humans; Infant, Newborn; Macular Degeneration; Neovascularization, Pathologic; Ranibizumab; Retinal Diseases; Retinopathy of Prematurity; Vascular Diseases

2007

Other Studies

7 other study(ies) available for almagate and Angiogenesis, Pathologic

ArticleYear
Effect of Topical Instillation of Pegaptanib Sodium Upon Inflammatory Corneal Neovascularization in Rabbits.
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2021, Volume: 37, Issue:5

    Topics: Administration, Topical; Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Aptamers, Nucleotide; Caustics; Cornea; Corneal Injuries; Corneal Neovascularization; Disease Models, Animal; Inflammation; Instillation, Drug; Male; Neovascularization, Pathologic; Prednisolone; Rabbits; Sodium Hydroxide; Treatment Outcome; Vascular Endothelial Growth Factor A

2021
Association of neovascular age-related macular degeneration with month and season of birth in Italy.
    Aging, 2016, 12-19, Volume: 9, Issue:1

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Female; Humans; Incidence; Italy; Macular Degeneration; Male; Neovascularization, Pathologic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Registries; Seasons; Treatment Outcome; Vascular Endothelial Growth Factor A

2016
Rapid and persistent regression of severe new vessels on the disc in proliferative diabetic retinopathy after a single intravitreal injection of pegaptanib.
    Acta ophthalmologica, 2009, Volume: 87, Issue:6

    Topics: Adult; Aptamers, Nucleotide; Diabetic Retinopathy; Female; Humans; Neovascularization, Pathologic; Optic Disk; Remission Induction; Severity of Illness Index; Vascular Endothelial Growth Factor A

2009
Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:17

    Topics: Angiogenesis Inhibitors; Animals; Aptamers, Nucleotide; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Disease-Free Survival; Female; Glioblastoma; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; Treatment Outcome; Vascular Endothelial Growth Factor A

2009
A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165.
    Proceedings of the National Academy of Sciences of the United States of America, 2005, Dec-27, Volume: 102, Issue:52

    Topics: Aptamers, Nucleotide; Binding Sites; Binding, Competitive; Cells, Cultured; Dimerization; Endothelium, Vascular; Heparin; Humans; Macular Degeneration; Magnetic Resonance Spectroscopy; Models, Molecular; Neovascularization, Pathologic; Pichia; Polyethylene Glycols; Protein Binding; Protein Conformation; Protein Isoforms; Protein Structure, Secondary; Protein Structure, Tertiary; Pyrimidines; RNA; Signal Transduction; Thermodynamics; Vascular Endothelial Growth Factor A

2005
Pegaptanib as an adjunctive treatment for complicated neovascular diabetic retinopathy.
    Archives of ophthalmology (Chicago, Ill. : 1960), 2006, Volume: 124, Issue:6

    Topics: Aptamers, Nucleotide; Chemotherapy, Adjuvant; Diabetic Retinopathy; Glaucoma Drainage Implants; Glaucoma, Neovascular; Gonioscopy; Humans; Injections; Iris; Lens Implantation, Intraocular; Male; Middle Aged; Neovascularization, Pathologic; Phacoemulsification; Postoperative Complications; Vitrectomy

2006
From proteins to nucleic acid-based drugs: the role of biotech in anti-VEGF therapy.
    Anti-cancer agents in medicinal chemistry, 2006, Volume: 6, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Controlled Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; Humans; Mice; Neoplasms; Neovascularization, Pathologic; Protein Engineering; Ranibizumab; RNA, Small Interfering; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors

2006